Researchers contend the "totality of evidence" for biosimilar approval may be sufficient to demonstrate interchangeability.
A group of researchers from the biosimilar industry and academia have recommended in a review that the FDA widen the scope of acceptable studies for determining interchangeable status for biosimilars.
Interchangeability is a status that would enable pharmacists to make an automatic switch from reference product to biosimilar at the prescription counter without doctor consultation. No biosimilars have yet met the requirements for this designation, although interchangeability is considered important for the uptake of biosimilars and potential savings.
For biosimilars to meet the requirements for interchangeability, they must be shown to produce the same clinical result as the reference product and pose no greater risks of diminished efficacy than if patients remained on the reference product.
Challenges of PK Parameters
The authors, who include Pfizer employees, argue that use of pharmacokinetic (PK) parameters for evaluating potential differences in immunogenicity between reference and biosimilar products is challenging and that interchangeability should be “assessed on a case by case basis, considering the ‘totality of the evidence’ and biologic plausibility.
“Alternative approaches to statistical analysis (eg, use of asymmetric rather than symmetric margins to test equivalence) and study designs that meet the FDA’s expectations for demonstration of interchangeability should be considered,” they wrote.
The authors contend that interchangeability studies as required by the FDA are complicated and are not required by European regulatory authorities. “Without requiring additional clinical studies, individual national authorities in the European Union may endorse the switching from 1 reference or biosimilar product to another at the pharmacy level without consent of the prescriber,” they said.
“By definition, the biosimilar has already been deemed by the FDA not to be clinically different from the reference product. As such, there is little reason to expect altered PK, heightened immunogenicity response, increased safety risk, or improved or diminished efficacy in patients who switch back and forth from a reference product to the corresponding biosimilar.”
One reason the FDA has given for requiring immunogenicity studies is to demonstrate, beyond the existing body of evidence on biosimilar efficacy and safety, that multiple switches between reference and biosimilar drugs would not result in a different outcome; however, the authors contend that the “perceived drawback of multiple switching…is based on theoretical concerns and experience with switches between one biologic product and another that is different, and not its biosimilar.”
“There is a low likelihood that the incidence, titers, or specificity of antidrug antibodies will increase or change as a result of multiple switches between a reference product and its biosimilar,” the authors wrote.
Reference
Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of biosimilars: what level of clinical evidence is needed to support the interchangeability designation in the United States? BioDrugs. Published online September 29, 2020. doi:10.1007/s40259-020-00446-7
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.